Table 9.
Changes in the Outcome Variables of the Subjects According to PPAR-γ2 Polymorphism
| Bofutsushosan | ||||
|---|---|---|---|---|
| Genotypea | Pre | Post | P valueb | |
| Body weight, kg | Pro/Pro | 74.74±11.18 | 73.83±10.83 | .0007* |
| Pro/Ala | 72.42±9.48 | 72.04±9.84 | .4971 | |
| BMI, kg/m2 | Pro/Pro | 29.84±6.38 | 29.51±6.42 | .0011* |
| Pro/Ala | 28.46±3.57 | 28.3±3.63 | .4997 | |
| WC, cm | Pro/Pro | 97.41±7.48 | 95.33±7 | .0007* |
| Pro/Ala | 99.9±7.55 | 94.83±3.88 | .2529 | |
| Body fat percent | Pro/Pro | 38.46±4.92 | 37.65±5.3 | .0108* |
| Pro/Ala | 36.96±6.01 | 35.27±2.71 | .6304 | |
| Body fat mass, kg | Pro/Pro | 28.75±5.97 | 27.66±5.65 | .0006* |
| Pro/Ala | 27.2±8.36 | 24.27±2.6 | .5254 | |
| RMR, kcal/d | Pro/Pro | 1405.2±393.65 | 1424.1±317.29 | .9526 |
| Pro/Ala | 1312±279.05 | 1240±240 | .7511 | |
| TG, mg/dL | Pro/Pro | 122.5±52.27 | 112.59±55.28 | .8844† |
| Pro/Ala | 175.8±98.47 | 187±16 | .1888 | |
| T-Chol, mg/dL | Pro/Pro | 206.28±39.46 | 195.72±35.42 | .0284* |
| Pro/Ala | 221.8±39.59 | 200.33±24.01 | .2013 | |
| HDL-Chol, mg/dL | Pro/Pro | 54.64±14.94 | 53.13±12.06 | .0101* |
| Pro/Ala | 61.6±11.22 | 71±10.15 | .0488*† | |
| Fasting BST, mg/dL | Pro/Pro | 98.9±9.71 | 98.03±11.13 | .8444 |
| Pro/Ala | 100±4.18 | 98±5.29 | .849 | |
| SBP, mmHg | Pro/Pro | 119.12±12.39 | 118.44±12.8 | .5772 |
| Pro/Ala | 122.4±16.18 | 116±23.64 | .2415 | |
| DBP, mmHg | Pro/Pro | 75.46±9.36 | 75.85±8.45 | .8583 |
| Pro/Ala | 76.8±4.32 | 64.33±14.64 | .2049† | |
| PR, bpm | Pro/Pro | 76.76±9.09 | 74.28±8.77 | .053* |
| Pro/Ala | 71.6±10.16 | 69.33±3.79 | .5352 | |
a
Distribution (number of patients): Pro/Ala, 5; Pro/Pro, 50.
b
Pre- vs. post-treatment (by paired t test).
*
P<.05.
†
Significant difference (P<.05) between the allelic variants (by independent t test).